 BRIDGEWATER, N.J., May 06, 2022 GLOBE NEWSWIRE -- VYNE Therapeutics Inc. Nasdaq: VYNE VYNE or the Company, a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will present at LifeSci Partners virtual Immunology and Inflammation Symposium, taking place May 10th-11th, 2022. 